Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer

This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron

doxorubicin
cyclophosphamide
trastuzumab
herceptin
carboplatin
  • 29 views
  • 03 Jun, 2022
  • 17 locations
Triple Therapy for Postoperative Nausea and Vomiting in Laparoscopic Gastrointestinal Surgery

Postoperative nausea and vomiting (PONV) are common in patients, especially in patients at high risk. PONV may result in prolonged hospital stay and threaten patients' life. Because the etiology of PONV is very complex, there is an increasing focus on combining antiemetics from different classes for PONV prophylaxis. Fosaprepitant is …

  • 0 views
  • 26 May, 2022
  • 1 location
Oral Akynzeo vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)

MyRisk: Efficacy and safety evaluation of oral Akynzeo in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study. Antiemetic guidelines recommendations are based on the emetogenic potential of the chemotherapy. Chemotherapy (CT) agents are divided in Highly, Moderately, Low and …

  • 3 views
  • 25 Sep, 2021
  • 5 locations
The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs

This study sought to investigate the efficacy and safety of a three-drug combination antiemetic regimen of olanzapine combined with aprepitant and palonosetron for the prevention of

olanzapine
palonosetron
aprepitant
cavity
carcinoma
  • 0 views
  • 21 Mar, 2022
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin

This is a multicentre, single-arm, phase II study to investigate the safety and antiemetic efficacy of Akynzeo (a fixed dose combination of palonosetron and netupitant) plus dexamethasone in

palonosetron
absolute neutrophil count
akynzeo
emetic
dexamethasone
  • 7 views
  • 15 Feb, 2022
  • 1 location
Open Label Single Arm Study for NEPA [Oral Fixed-dose Combination of 300 mg Netupitant and 0.50 mg Palonosetron] in Hong Kong Oncology Patients Receiving (Neo)-Adjuvant Chemotherapy Treatment Consists of Adriamycin and Cyclophosphamide for Breast Cancer

response to conditions that affect the gut and the vomiting center, which is an area in the brain. Netupitant and palonosetron are drugs that are thought to block the activation of certain types of

adjuvant chemotherapy
cyclophosphamide
cancer treatment
mammogram
immunostimulant
  • 0 views
  • 15 Oct, 2022
  • 1 location
Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma

This is an open-label, multi-center, prospective, single arm phase 2 trial of the combination of bendamustine and rituximab in patients with PTLD, monomorphic cluster of differentiation antigen 20(CD20) positive DLBCL. The investigators want to investigate the efficacy and safety of the combination of bendamustine and rituximab in patients with previously …

rituximab
b-cell lymphoma
renal function
neutrophil count
measurable disease
  • 11 views
  • 21 Jan, 2021
  • 1 location
Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration

This is an open label study for any patients with a bile duct cancer or gallbladder cancer, who will be treated with gemcitabine and cisplatin chemotherapy (the ABC02 regime). Patients recruited onto this study will have a reduction of their hydration time and be given Akynzeo as an anti-sickness drug, …

renal function
cholangiocarcinoma
gemcitabine
akynzeo
carcinoma
  • 4 views
  • 04 Oct, 2022
  • 1 location